• Research activities

    Dendritic cells (DC) comprise a family of professional antigen presenting cells unique in their capacity to modulate T cell responses. DC play a primary role in pathogen protection, in central and peripheral tolerance and in anticancer immune responses. In our unit we have two major lines of research:

    We are using bacteria to successfully exploit antigen presentation and to develop new ways to target tumor antigens into dendritic cells. We are also using bacteria to target tumor cells via the generation of intelligent missiles that will recognize only tumor cells and will deliver payloads of enzymes important for the catabolization of prodrugs into active anticancer agents. Finally, we are trying to understand the mechanism of resistance to tumor targeted therapy that involves the activation of the immune system.

    In the second line of research, as a deregulation in bacterial handling has been associated with the development of inflammatory bowel disease, we want to understand the basis of bacterial handling in the gut. We found that even though dendritic cells encounter bacteria in the gut they are inhibited in their inflammatory potential. We are studying how deregulation in bacteria handling can affect the homeostasis of the gut and eventually lead to cancer or inflammatory bowel disorders.

  • Educational activities

    Since 2001 faculty member of SEMM.

    Coordinator of SIPOD: Structured international Post-doctoral programme
    Organizer of the Immunology course for the PhD programme
    Organizer of the Clinical trial course for the SIPOD

    2007-2012 Visiting Professor University of Oslo

  • Publications

    Selected from 114

    • 1. Mazzini E, Massimiliano L, Penna G, Rescigno M. Oral Tolerance Can Be Established via Gap Junction Transfer of Fed Antigens from CX3CR1+ Macrophages to CD103+ Dendritic Cells. Immunity. 2014 Jan 21. pii: S1074-7613(14)00003-X. doi: 10.1016/j.immuni.2013.12.012. [Epub ahead of print]
    • 2. Massa PE, Paniccia A, Monegal A, de Marco A, Rescigno M. Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. Blood. 2013 Jun 4. [Epub ahead of print]
    • 3. Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010 Jul 7;29(13):2242-52.
    • 4. Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P, Rescigno M. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2010 Aug 11;2(44):44ra57.
    • 5. Rimoldi, M., Chieppa, M., Salucci, V., Sonzogni, A., Nespoli, A., Viale, G., Allavena, P., Rescigno, M. Intestinal immune homeostasis is regulated by the cross-talk between epithelial cells and dendritic cells. (2005) Nat Immunol. 6:507-14.



Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus


Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153 - Codice intermediario fatturazione elettronica: A4707H7